Back to results
US 2023/0065827 A1Published application
Immunomodulators
AssigneeBristol-Myers Squibb Company
InventorsTao WANG, Paul Michael SCOLA, Zhongxing ZHANG
Life of this patent
Estimating the term…
Abstract
In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
Claims13
A compound of formula (I)
- or a pharmaceutically acceptable salt thereof, wherein:
- Rx and Ry are independently H,
- provided that at least one of Rx and Ry is other than H;
- R1 is H, halogen or C1-C6 alkyl;
- R2 and R3 are independently H, halogen, C1-C6 alkyl, or aryl;
- said aryl group substituted with 0-3 R3a;
- R3a is halogen or COOR4;
- R4 is H or C1-C6 alkyl;
- and
- R9 is H or C1-C3 alkyl.
7 more elements
Dependencies are inferred from the claim text.